Skip to main content
ADPT
NASDAQ Life Sciences

Adaptive 10-Q: Q3 Revenue $83.9M, Net Income $2.9M, Cash $400.2M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$28.48
Mkt Cap
$4.263B
52W Low
$12
52W High
$30.74
52W Position info
137% above low
Off High info
7.4% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ADPT has more than doubled off its 52-week low of $12.

Summary

Adaptive's Q3 10-Q shows MRD revenue up 28% to $72.6 million, a $2.9 million quarterly profit, and $400.2 million in cash and securities after the June convertible notes deal, while Immune Medicine revenue fell 70% as Genentech revenue ended.


Key Events · Earnings and Guidance · ADPT

  • Q3 Revenue $83.9M, Small Quarterly Profit

    Total revenue of $83.9 million produced net income attributable to Adaptive of $2.9 million, or $0.02 per share, versus $9.5 million in Q3 2025.

  • MRD Growth Offsets Immune Medicine Decline

    MRD revenue rose 28% to $72.6 million on 39,587 clonoSEQ tests (up 46%), while Immune Medicine revenue fell 70% to $11.3 million after the Genentech collaboration ended.

  • Cash $400.2M After Convertible Notes

    Cash, cash equivalents and marketable securities were $400.2 million at September 30, 2026 versus $240.2 million at year-end, following the $345.0 million 0% convertible notes issued June 22, 2026 and the $156.9 million OrbiMed royalty buyout.

  • Operating Cash Burn Narrows Sharply

    Nine-month net cash used in operating activities was $6.3 million versus $48.0 million a year earlier, helped by higher customer collections; management says existing cash funds operations for at least the next 12 months.


Analysis · ADPT · Life Sciences

The headline revenue number was already out via Reuters and a concurrent 8-K, but the full 10-Q is where the balance sheet and cash story lives. MRD revenue grew 28% to $72.6 million on 46% higher clonoSEQ test volume, and the company swung to a small $2.9 million quarterly profit. More important for the thesis: cash and marketable securities stand at $400.2 million after the June convertible notes offering and the $156.9 million OrbiMed royalty buyout, and nine-month operating cash burn narrowed to $6.3 million from $48.0 million a year ago. Against that, Immune Medicine revenue fell 70% to $11.3 million as Genentech collaboration revenue disappeared, and the segment posted a $13.4 million nine-month Adjusted EBITDA loss while the separation review continues. The filing also discloses new 10b5-1 plans for the CEO and five other insiders, and a new data-hosting agreement with Harlan Robins' Harell Data Corp. — a related-party arrangement worth noting alongside the ongoing Immune Medicine separation.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADPT was trading at $28.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $12.00 to $30.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $28.80
Real-time Price: $28.78 info
Change: -$0.0249 (-0.09%) info
Market Cap: $4.658B info
ADPT
Sep 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $27.98
Real-time Price: $28.78 info
Change: +$0.795 (+3%) info
Market Cap: $4.658B info
ADPT
Aug 19, 2026, 8:15 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $25.80
Real-time Price: $28.78 info
Change: +$2.97 (+12%) info
Market Cap: $4.658B info
ADPT
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.66
Real-time Price: $28.78 info
Change: +$4.11 (+17%) info
Market Cap: $4.658B info
ADPT
Jul 29, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.15
Real-time Price: $28.78 info
Change: +$6.62 (+30%) info
Market Cap: $4.658B info